Manufacturing

Articles

Tackling process development early on can better optimize manufacturing processes for emerging therapies.

Optimizing Process Development for Emerging Therapies

The growing interest in developing cell and gene therapies has prompted industry investment to grow manufacturing capacity.

Investments Inject Growth in Cell and Gene Therapies

The expansion gives the company diversified capacity running cell production lines featuring Sartorius-brand 2000-L disposable bioreactors and now GE-brand 2000-L single-use bioreactors.

MabPlex Launches New 2000-L Cell Culture Production Lines

The company presented data on its G2 glycosylation studies at the 15th European Conference on Fungal Genetics in Rome on Feb. 19, 2020.

Dyadic Achieves G2 Human-Like Glycosylation Milestone

The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.

WuXi Biologics Provides Update on Operations in Light of Coronavirus Outbreak

The new facility includes six classified environment rooms with space to expand.

Hitachi Chemical Opens New Cell and Gene Therapy Manufacturing Facility

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech. 

Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost. 

Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.

More Capacity and Technology Translate to More Options

The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.

The Discovery Labs, Deerfield Management Create New CDMO and Invest $1.1 Billion in New Cell and Gene Therapy Facility

The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.

Manufacturing, Biologic Drugs